These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 32160077)
61. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma]. Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123 [TBL] [Abstract][Full Text] [Related]
62. Early treatment for high-risk smouldering myeloma: has the time come? Ludwig H Lancet Oncol; 2016 Aug; 17(8):1030-1032. PubMed ID: 27402144 [No Abstract] [Full Text] [Related]
63. Smoldering multiple myeloma: when to observe and when to treat? Mateos MV; San Miguel JF Am Soc Clin Oncol Educ Book; 2015; ():e484-92. PubMed ID: 25993213 [TBL] [Abstract][Full Text] [Related]
64. Effect of low-dose bortezomib on bone formation in smouldering multiple myeloma. Hildebrandt GC; Berno T; Gurule A; Mohan M; Yoon D; Salama M; Zangari M Br J Haematol; 2019 Jan; 184(2):308-310. PubMed ID: 29574687 [No Abstract] [Full Text] [Related]
65. Lenalidomide plus dexamethasone versus observation in patients with high-risk smouldering multiple myeloma (QuiRedex): long-term follow-up of a randomised, controlled, phase 3 trial. Mateos MV; Hernández MT; Giraldo P; de la Rubia J; de Arriba F; Corral LL; Rosiñol L; Paiva B; Palomera L; Bargay J; Oriol A; Prosper F; López J; Arguiñano JM; Quintana N; García JL; Bladé J; Lahuerta JJ; Miguel JS Lancet Oncol; 2016 Aug; 17(8):1127-1136. PubMed ID: 27402145 [TBL] [Abstract][Full Text] [Related]
66. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Atrash S; Robinson M; Slaughter D; Aneralla A; Brown T; Robinson J; Ndiaye A; Sprouse C; Zhang Q; Symanowski JT; Friend R; Voorhees PM; Usmani SZ; Bhutani M Blood Cancer J; 2018 Nov; 8(11):107. PubMed ID: 30410066 [No Abstract] [Full Text] [Related]
67. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M; Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405 [TBL] [Abstract][Full Text] [Related]
69. Advances in the management of asymptomatic myeloma. Mateos MV Curr Opin Oncol; 2014 Nov; 26(6):670-6. PubMed ID: 25210868 [TBL] [Abstract][Full Text] [Related]
70. Smoldering multiple myeloma: the role of different scoring systems in identifying high-risk patients in real-life practice. Cocito F; Mangiacavalli S; Ferretti VV; Cartia CS; Ganzetti M; Benveuti P; Pompa A; Catalano M; Fugazza E; Landini B; Arcaini L; Corso A Leuk Lymphoma; 2019 Dec; 60(12):2968-2974. PubMed ID: 31169049 [TBL] [Abstract][Full Text] [Related]
71. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology. Mateos MV; Landgren O Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254 [TBL] [Abstract][Full Text] [Related]
72. Impact of disease status on outcome in relapsed and refractory multiple myeloma treated with lenalidomide. Nozzoli C; Staderini M; Veltroni A; Longo G; Bacchiarri F; Donnini I; Guarrera A; Bosi A Leuk Lymphoma; 2015; 56(8):2388-91. PubMed ID: 25535816 [TBL] [Abstract][Full Text] [Related]
75. Remission induction with lenalidomide alone in a patient with previously untreated plasmablastic myeloma: a case report. Sher T; Miller KC; Lee K; Chanan-Khan A Clin Lymphoma Myeloma; 2009 Aug; 9(4):328-30. PubMed ID: 19717386 [TBL] [Abstract][Full Text] [Related]
76. Treatment Outcomes and Health Care Resource Utilization in Patients With Newly Diagnosed Multiple Myeloma Receiving Lenalidomide-only Maintenance, Any Maintenance, or No Maintenance: Results from the Connect MM Registry. Rifkin RM; Jagannath S; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Parikh K; Abouzaid S; Srinivasan S; Kitali A; Zafar F; Abonour R Clin Ther; 2018 Jul; 40(7):1193-1202.e1. PubMed ID: 30007443 [TBL] [Abstract][Full Text] [Related]
77. Review of therapy for relapsed/refractory multiple myeloma: focus on lenalidomide. Mariz JM; Esteves GV Curr Opin Oncol; 2012 Jan; 24 Suppl 2():S3-11. PubMed ID: 22245806 [TBL] [Abstract][Full Text] [Related]
78. The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy. Tzogani K; Camarero Jiménez J; Garcia I; Sancho-López A; Martin M; Moreau A; Demolis P; Salmonson T; Bergh J; Laane E; Ludwig H; Gisselbrecht C; Pignatti F Oncologist; 2017 Nov; 22(11):1339-1346. PubMed ID: 28935772 [TBL] [Abstract][Full Text] [Related]
79. Diagnosis and management of smoldering multiple myeloma: the razor's edge between clonality and cancer. Muchtar E; Kumar SK; Magen H; Gertz MA Leuk Lymphoma; 2018 Feb; 59(2):288-299. PubMed ID: 28592156 [TBL] [Abstract][Full Text] [Related]
80. Retreatment with lenalidomide is an effective option in heavily pretreated refractory multiple myeloma patients. Stork M; Sevcikova S; Adam Z; Krejci M; Sandecka V; Kral Z; Brozova L; Velichova R; Pour L Neoplasma; 2018; 65(4):585-591. PubMed ID: 29940759 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]